Gabrielle Paloma Acquaro, MD | |
2516 E Dupont Rd, Fort Wayne, IN 46825-1608 | |
(260) 458-3740 | |
(260) 458-3741 |
Full Name | Gabrielle Paloma Acquaro |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 2516 E Dupont Rd, Fort Wayne, Indiana |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1649625104 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 01081702A (Indiana) | Primary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Gabrielle Paloma Acquaro, MD 6920 Pointe Inverness Way Ste 200, Fort Wayne, IN 46804-7934 Ph: (260) 458-3740 | Gabrielle Paloma Acquaro, MD 2516 E Dupont Rd, Fort Wayne, IN 46825-1608 Ph: (260) 458-3740 |
News Archive
Oncotarget published "Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations" which reported that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients.
An innovative systems biology approach to understanding the carbohydrate structures in cells is leading to new ways to understand how inflammatory illnesses and cardiovascular disease develop in humans. The work was described in two recent publications by University at Buffalo chemical engineers.
A dendritic cell vaccine personalized for each individual based on the patient's own tumor may increase median survival time in those with a deadly form of brain cancer called glioblastoma, an early phase study at UCLA's Jonsson Comprehensive Cancer Center has found.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
Updated clinical trial results show that the drug dasatinib (Sprycel) continues to be highly effective in patients with chronic myelogenous leukemia who were unable to tolerate Gleevec or who developed resistance to it, reports a team led by researchers at Dana-Farber Cancer Institute.
› Verified 6 days ago
Rebecca Mason, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8233 Glencarin Blvd, Fort Wayne, IN 46804 Phone: 260-425-5470 Fax: 260-425-5475 | |
Anthony D Dennis, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 11635 Coldwater Rd, Fort Wayne, IN 46845 Phone: 260-637-1661 Fax: 260-637-1601 | |
Dr. Charles R Pattan, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11050 Parkview Circle Dr, Fort Wayne, IN 46845 Phone: 833-724-8326 Fax: 260-266-8941 | |
Gregory L Chupp, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 3909 New Vision Dr, Fort Wayne, IN 46845 Phone: 260-469-6610 | |
Christina Mcguirk, Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 2200 Randallia Dr, Fort Wayne, IN 46805 Phone: 260-373-4000 | |
Samantha Dawn Warden, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 750 Broadway Ste 350, Fort Wayne, IN 46802 Phone: 260-423-2675 Fax: 260-423-6621 | |
Dr. Mary Ann O'brien, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3909 New Vision Dr, Fort Wayne, IN 46845 Phone: 260-496-6602 Fax: 260-969-3065 |